The Gastrointestinal and Gastroesophageal Reflux (GIGER) Scale for Infants and Toddlers.
Britt F Pados, Christine Repsha, Rebecca R Hill
https://pubmed.ncbi.nlm.nih.gov/34350308/Actively Recruiting
Led by United Pharmaceuticals · Updated on 2025-01-06
139
Participants Needed
4
Research Sites
17 weeks
Total Duration
Researchers are studying infants with functional gastrointestinal disorders FGIDs to see how these conditions change when fed a new infant formula. This open-label, interventional, non-comparative multicenter study uses the Gastrointestinal and Gastroesophageal Reflux GIGER scale to evaluate symptoms like regurgitations, colic, and constipation. The study focuses on infants up to 4 months old who have at least one FGID based on adapted Rome IV criteria. The study involves feeding infants a thickened infant formula containing fibers and probiotics over two periods a first 30-day period followed by an optional 90-day intervention period. The new formula is given continuously during the total 4-month study duration. Researchers will monitor various symptoms and digestive functions using the GIGER scale and other assessments throughout these periods. Participants will be evaluated regularly with measures including regurgitation frequency and severity, stool characteristics, colic, gas severity, abdominal distension, sleep quality, infant growth parameters, and quality of life. Parents will also report satisfaction. Safety is monitored by recording any adverse events through study completion. The primary outcome is the change in GIGER score from baseline at Day 30, with ongoing assessments up to Day 120 for those continuing in the optional period.
CONDITIONS
Evolution of Functional Gastrointestinal Disorders in Infants Fed With a New Infant Formula
A
Anne-Sophie Garreau
C
Caroline Thevret, Dr.
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
United Pharmaceuticals
Lead Sponsor
Axiodis CRO
Collaborating Sponsor
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - 30 days
Participants receive the new infant formula during the initial 30-day study period.
Visits on Days 7, 14, and 30
Duration - 90 days
Participants may continue receiving the new infant formula for an additional 90 days.
Visits on Days 60, 90, and 120
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
OTHER
Number of Arms
1
Have more questions? Get in touch with our team for quick support
Britt F Pados, Christine Repsha, Rebecca R Hill
https://pubmed.ncbi.nlm.nih.gov/34350308/S Manificat, A Dazord, J Langue...
https://pubmed.ncbi.nlm.nih.gov/10911526/Y Vandenplas, S Hachimi-Idrissi, A Casteels...
https://pubmed.ncbi.nlm.nih.gov/8088297/Koen Huysentruyt, Ilan Koppen, Marc Benninga...
https://pubmed.ncbi.nlm.nih.gov/30672767/United Pharmaceuticals
Lead Sponsor
Axiodis CRO
Collaborating Sponsor